TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -15.42%14.41B | 11.92%34.76B | 21.28%17.04B | 15.17%31.06B | 13.54%14.05B | 39.29%26.97B | 63.92%12.38B | 61.76%19.36B | 85.29%7.55B | 20.69%11.97B |
Operating income | -15.42%14.41B | 11.92%34.76B | 21.28%17.04B | 15.17%31.06B | 13.54%14.05B | 39.29%26.97B | 63.92%12.38B | 61.76%19.36B | 85.29%7.55B | 20.69%11.97B |
Cost of sales | 16.57%-11.82B | -13.49%-28.88B | -22.84%-14.17B | -11.28%-25.45B | -9.52%-11.53B | -40.39%-22.87B | -69.20%-10.53B | -64.68%-16.29B | -83.52%-6.22B | -19.20%-9.89B |
Operating expenses | 16.57%-11.82B | -13.49%-28.88B | -22.84%-14.17B | -11.28%-25.45B | -9.52%-11.53B | -40.39%-22.87B | -69.20%-10.53B | -64.68%-16.29B | -83.52%-6.22B | -19.20%-9.89B |
Gross profit | -9.75%2.59B | 4.83%5.89B | 14.13%2.87B | 36.88%5.61B | 36.46%2.52B | 33.46%4.1B | 39.13%1.85B | 47.88%3.07B | 94.10%1.33B | 28.31%2.08B |
Selling expenses | 26.21%-605.72M | -5.69%-1.44B | -29.09%-820.88M | -5.86%-1.36B | -5.14%-635.88M | -37.23%-1.28B | -34.01%-604.79M | -17.93%-934.91M | -105.06%-451.31M | -36.27%-792.8M |
Administrative expenses | 10.84%-420.3M | -23.35%-1.11B | -0.94%-471.38M | -9.57%-896.14M | -33.67%-467M | -36.89%-817.89M | -18.64%-349.37M | -23.40%-597.48M | -51.47%-294.48M | -16.05%-484.17M |
Research and development expenses | 11.48%-491.11M | -7.79%-1.19B | -9.79%-554.82M | -31.07%-1.11B | -49.09%-505.35M | -39.40%-843.69M | -63.17%-338.95M | -56.74%-605.22M | -68.24%-207.73M | -26.42%-386.14M |
Special items of operating profit | -43.18%251.27M | 115.93%979.77M | 102.64%442.26M | 19.30%453.74M | 28.43%218.25M | 47.36%380.32M | 54.69%169.93M | 37.72%258.09M | 43.78%109.86M | 13.98%187.41M |
Operating profit | -9.62%1.33B | 15.68%3.13B | 30.23%1.47B | 76.13%2.71B | 56.22%1.13B | 28.78%1.54B | 49.61%722.21M | 98.15%1.19B | 117.68%482.73M | 25.62%602.43M |
Financing cost | 10.23%-19.85M | 25.52%-44.24M | 26.04%-22.11M | -288.64%-59.4M | -308.69%-29.9M | -235.91%-15.28M | -431.61%-7.32M | -105.32%-4.55M | -0.51%-1.38M | -173.92%-2.22M |
Special items of earning before tax | 55.75%-5.3M | -106.19%-67.89M | 22.98%-11.97M | -119.09%-32.93M | -399.58%-15.54M | -533.29%-15.03M | ---3.11M | ---2.37M | ---- | ---- |
Earning before tax | -9.23%1.3B | 15.47%3.02B | 32.55%1.44B | 73.54%2.62B | 52.13%1.08B | 26.98%1.51B | 47.87%711.78M | 97.72%1.19B | 118.41%481.35M | 25.37%600.22M |
Tax | -8.25%-268.95M | 12.14%-379.79M | -39.36%-248.45M | -208.01%-432.27M | -41.71%-178.28M | 38.31%-140.34M | -48.13%-125.81M | -148.56%-227.49M | -117.36%-84.93M | -97.14%-91.52M |
After-tax profit from continuing operations | -12.89%1.03B | 20.94%2.64B | 31.21%1.19B | 59.73%2.18B | 54.36%904.53M | 42.46%1.37B | 47.82%585.98M | 88.58%959.29M | 118.64%396.42M | 17.67%508.69M |
Earning after tax | -12.89%1.03B | 20.94%2.64B | 31.21%1.19B | 59.73%2.18B | 54.36%904.53M | 42.46%1.37B | 47.82%585.98M | 88.58%959.29M | 118.64%396.42M | 17.67%508.69M |
Minority profit | ---- | ---- | -115.43%-856K | 868.09%21.91M | 274.13%5.55M | -250.11%-2.85M | -302.61%-3.19M | -50.76%1.9M | 23.39%1.57M | 201.25%3.86M |
Profit attributable to shareholders | -12.95%1.03B | 22.17%2.64B | 32.11%1.19B | 57.80%2.16B | 52.59%898.98M | 43.04%1.37B | 49.21%589.16M | 89.64%957.39M | 119.31%394.85M | 17.12%504.83M |
Basic earnings per share | -13.53%0.345 | 19.59%0.885 | 28.30%0.399 | 54.81%0.74 | 50.97%0.311 | 43.11%0.478 | 50.36%0.206 | 95.32%0.334 | 124.59%0.137 | 18.75%0.171 |
Diluted earnings per share | -12.91%0.344 | 20.71%0.88 | 28.66%0.395 | 55.11%0.729 | 51.98%0.307 | 43.29%0.47 | 48.53%0.202 | 91.81%0.328 | 122.95%0.136 | 0.171 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.